Get started
Author

Jessica Tran

ORCID: 0009-0008-7679-0762
Observed ORCIDs: 0009-0008-7679-0762, 0009-0006-2545-6858
OpenAlex ID: A5074139894
Gold nanocluster adjuvant enables the eradication of persister cells by antibiotics and abolishes the emergence of resistance
2022 · Zhixin Cao, Xiaohua Chen, et al. · Nanoscale · 26
Antimicrobial Gold Nanoclusters Eradicate Escherichia coli Biofilms and Are Nontoxic by Oral Administration
2020 · Zhixin Cao, Jing Chen, et al. · ACS Applied Bio Materials · 13
First, do NOHARM: a medical safety benchmark and randomized study of physician and AI teaming on clinical consultations
2025 · Wu, David, Haredasht, Fateme Nateghi, et al. · arXiv (Cornell University) · 7
PDF
Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025 · Linjie Yuan, Wenzhi Ji, et al. · Cancer Discovery · 5
The PHB Granule Biogenesis Pathway in Caulobacter
2023 · Edward A. de Koning, Mayura Panjalingam, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 3
PDF
Automated evaluation of large language model response concordance with human specialist responses on physician-to-physician eConsult cases
2025 · David Wu, Fateme Haredasht, et al. · 1
Automated Evaluation of Large Language Model Response Concordance with Human Specialist Responses on Physician-to-Physician eConsult Cases
2025 · David JH Wu, Fateme Nateghi Haredasht, et al. · medRxiv · 1
PDF
Pediatric gastrointestinal surgical site infections: a case–control study
2026 · Vicky Khoury, Erika P. Viana Cardenas, et al. · Infection Control and Hospital Epidemiology
PDF
58 Bridging the gap: reducing hospital readmissions through the stanford health care at home program
2026 · Jessica Tran, Shivam Vedak, et al.
PDF
Data from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025 · Linjie Yuan, Wenzhi Ji, et al.
Figure S1 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025 · Linjie Yuan, Wenzhi Ji, et al.
PDF
Figure S11 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025 · Linjie Yuan, Wenzhi Ji, et al.
PDF
Figure S2 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025 · Linjie Yuan, Wenzhi Ji, et al.
PDF
Figure S4 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025 · Linjie Yuan, Wenzhi Ji, et al.
PDF
Figure S3 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025 · Linjie Yuan, Wenzhi Ji, et al.
PDF
Figure S13 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025 · Linjie Yuan, Wenzhi Ji, et al.
PDF
Figure S12 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025 · Linjie Yuan, Wenzhi Ji, et al.
PDF
Figure S10 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025 · Linjie Yuan, Wenzhi Ji, et al.
PDF
Figure S6 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025 · Linjie Yuan, Wenzhi Ji, et al.
PDF
Supplementary Methods S1 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025 · Linjie Yuan, Wenzhi Ji, et al.
PDF
Figure S7 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025 · Linjie Yuan, Wenzhi Ji, et al.
PDF
Figure S9 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025 · Linjie Yuan, Wenzhi Ji, et al.
PDF
Figure S8 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025 · Linjie Yuan, Wenzhi Ji, et al.
PDF
Figure S5 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025 · Linjie Yuan, Wenzhi Ji, et al.
PDF
Tables S1-S11 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025 · Linjie Yuan, Wenzhi Ji, et al.
Works count: 25
Citation count: 47
H-index: 3
I10-index: 2
Year
Topic
Type